December 2022
Volume 22, Issue 14
Open Access
Vision Sciences Society Annual Meeting Abstract  |   December 2022
Neurochemical markers of degeneration in the visual cortex after vision loss from Stargardt macular dystrophy
Author Affiliations & Notes
  • Aislin Sheldon
    Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neuroscience, University of Oxford
  • Jasleen Jolly
    Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neuroscience, University of Oxford
    Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neuroscience, University of Oxford
    Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust
    Vision and Eye Research Institute, Anglia Ruskin University, Cambridge
  • Betina Ip
    Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neuroscience, University of Oxford
  • William Clarke
    Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neuroscience, University of Oxford
  • Saad Jbabdi
    Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neuroscience, University of Oxford
  • Susan Downes
    Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neuroscience, University of Oxford
    Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust
  • Holly Bridge
    Oxford Centre for Functional Magnetic Resonance Imaging of the Brain (FMRIB), Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neuroscience, University of Oxford
  • Footnotes
    Acknowledgements  With thanks to the Medical Research Council, the Nuffield Department of Clinical Neuroscience and Eurofins Scientific for the funding support.
Journal of Vision December 2022, Vol.22, 4331. doi:https://doi.org/10.1167/jov.22.14.4331
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Aislin Sheldon, Jasleen Jolly, Betina Ip, William Clarke, Saad Jbabdi, Susan Downes, Holly Bridge; Neurochemical markers of degeneration in the visual cortex after vision loss from Stargardt macular dystrophy. Journal of Vision 2022;22(14):4331. https://doi.org/10.1167/jov.22.14.4331.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Stargardt macular dystrophy (STGD1) causes progressive degeneration of the photoreceptors in the retina, predominantly affecting the central macula. A focal region of vision loss in STGD1 is projected into a localised region of the primary visual cortex (V1). There are therapies in development that allow functional restoration of the retina, but it is unclear how the visual cortex will process restored visual input in adulthood. Loss of visual input will influence cortical processing, leading to degeneration that would be reflected in the local chemical environment. This study explores if vision loss from STGD1 affects in vivo neurochemistry by using high resolution Magnetic Resonance Spectroscopy Imaging (MRSI). STGD1 (n=16, mean age 34.0 ± 15.1 SD) were compared to normally sighted controls (n=14, mean age 38.7 ± 14.6 SD). A MRSI slab (resolution = 5x5x15mm, FOV=240x240x15mm) was placed in the occipital lobe. For each participant, neurochemical concentrations relative to total creatine were quantified in voxels constrained within V1 (defined by the Juelich atlas), averaged across voxels, and then compared between groups. The concentrations were then correlated with the extent of disease severity through visual field loss in STGD1 patients. Myo-inositol (a marker for glial cell proliferation) was higher within V1 in STGD1 compared to controls (t(28)=2.69; p=.012) and correlated with the extent of vision loss (higher concentrations related to greater loss; r(17)=-.68; p<.001). Glutamate (marker for neuronal function) (r(22)=.47; p=.022) and NAA (marker for neuronal integrity) (r(12)=.61 ;p=.020) correlated with the extent of vision loss (lower concentrations related to greater loss). These findings show a significant change in neurochemical concentrations related to glial and neuronal integrity in adults with vision loss compared to those without. The capacity for the visual cortex to process restored input should be considered alongside potential visual restoration therapies, as their effectiveness could be hindered by cortical degeneration.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×